VivoSeq
Oncology

Atypical Teratoid/rhabdoid Tumor

4

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Atypical Teratoid/Rhabdoid Tumor is an early-stage landscape with 4 programs across 3 companies. The most active players are Johnson & Johnson, Kazia Therapeutics Limited, Aminex Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2K

Kazia Therapeutics Limited

1 program

Phase 2A

Aminex Therapeutics, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Completed1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Completed·Children's Oncology Group·Phase 3·NCT00653068·70 enrolled
Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors
Active, not recruiting·TTaipei Medical University·Phase 2·NCT06853080·6 enrolled
A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas
Recruiting·MMilton S. Hershey Medical Center·Preclinical·NCT06465199·289 enrolled
A Platform Study of Novel Therapies for Children, Adolescents and Young Adults With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)
Recruiting·SSabine Mueller, MD, PhD·Phase 2·NCT07447076·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)